A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes - ATTAIN-2 - Eli Lilly and CompanySee more
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Urticaria
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. - Novartis PharmaceuticalsSee more
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria - EMBARQ-CSU1 - Celldex TherapeuticsSee more
Diabetes
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes - ATTAIN-2 - Eli Lilly and CompanySee more
Renal disease
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more